TabsDetailsBasic DetailsDate Posted: Tuesday, August 25, 2020Status: CompleteMedical Product: angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, sacubitril/valsartanDescription: In this analysis we examined counts of new users of sacubitril/valsartan, angiotensin-converting enzyme (ACE) inhibitors, and other angiotensin II receptor blockers (ARBs) with heart failure in the Sentinel Distributed Database (SDD). We also captured switching between products.This analysis include two reports containing data from 16 Data Partners contributing to the SDD. Data from January 1, 2015 to July 31, 2019 were included in Report 1, which was distributed on December 6, 2019. Data from January 1, 2015 to July 31, 2019 were included in Report 2, which was distributed on February 27, 2020. Read More Deliverables (2)Sentinel Modular Program Report: Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure, Report 1Sentinel Modular Program Report: Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure, Report 2Additional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2015 - July 31, 2019Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Individuals 18 years of age and olderData Sources: Sentinel Distributed Database (SDD)Related Links: Utilization of Sacubitril/Valsartan in Real-World SettingsICPE 2020: Utilization of Sacubitril/Valsartan in Real-World Settings